Answers are grounded in this paper and cite their sources.
Background: Coenzyme Q10 (CoQ10) is a biological quinone compound characterized by two primary physiological functions: acting as an antioxidant and serving as a crucial redox component within the mitochondrial respiratory chain. These specific activities may hold significant implications for both the prognosis and therapeutic management of breast cancer, which remains the most frequently diagnosed malignancy among women. Aim: This study aimed to investigate whether serum levels of CoQ10 are affected by adjuvant chemotherapy. Methodology: This study evaluated twenty-five Greek patients who had undergone surgical intervention followed by adjuvant chemotherapy with a favorable clinical response. To measure serum levels of CoQ10, blood samples were collected at three distinct time points during the course of treatment. Results: Baseline serum levels (35.26 ± 12.49) were significantly lower than those observed at mid-treatment (57.78 ± 10.88) and post-treatment (64.65 ± 8.97, p <0.0001). Furthermore, a statistically significant increase was maintained between the mid- and post-treatment intervals, with the highest values recorded at the conclusion of the study. Conclusion: Elevated levels of CoQ10 align with findings from prior research, indicating its potential utility as an auxiliary biomarker. However, given the absence of a control cohort and the limited sample size (n=25), these outcomes must be interpreted as exploratory and hypothesis-generating rather than definitive.
No takes yet. Share an insight, caveat, or question.
Dogkas et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: